Outlook Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
56.057MUSD
−0.2516USD
−66.052MUSD
260.245M
Beta
0.7

About Outlook Therapeutics, Inc.

CEO
C. Russell Trenary
Headquarters
Iselin
Employees
17
Founded
2010
ISIN
US69012T2069

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:
‪0‬
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Futures, Bonds
4.3Good

See all brokers